Generated by AI
IDEAYA Biosciences Inc. is a precision medicine oncology company focused on discovering and developing targeted therapies for cancers defined by specific genetic alterations and biomarker profiles. The company combines small-molecule drug discovery, structural biology, bioinformatics, and translational biomarker expertise to advance investigational medicines designed for molecularly selected patient populations. Its current portfolio spans synthetic lethality, targeted pathway inhibition, and antibody-drug conjugate research across solid tumors, including programs directed at uveal melanoma and other genetically defined cancers. IDEAYA Biosciences Inc. works with a research-driven model that integrates internal discovery capabilities with clinical development and collaboration-based programs, making it a notable participant in the broader oncology innovation landscape. Headquartered in South San Francisco, California, the company is positioned around precision oncology approaches intended to match treatments to the biological drivers of disease.
Website5000 Shoreline Court
South San Francisco, CA, 94080
United States
The latest articles about IDYA.
IDEAYA Biosciences (IDYA) is back in focus after outlining an FDA backed registrational plan for IDE849, its DLL3 targeted antibody drug conjugate in difficult neuroendocrine and small cell lung cancers. Against this clinical backdrop, IDEAYA Biosciences has seen momentum cool, with the share price down 9.72% over the past day and 16.56% over 30 days, contributing to a 29.48% decline over 90 days and a 19.03% year to date share price fall. However, the 5 year total shareholder return of...
Ideaya Biosciences is continuing to advance its first-in-class, oral, small-molecule protein kinase C [PKC] inhibitor darovasertib. I rate IDYA stock as Strong Buy.
Summary of Nov 18's posts. Generated by AI.
Summary of Apr 13's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about IDYA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.